Literature DB >> 25534731

Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Seyedmojtaba Seyedmousavi1, Johan W Mouton1, Willem J G Melchers2, Paul E Verweij3.   

Abstract

We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to azole-resistant Aspergillus fumigatus isolates. Using a neutropenic murine model of pulmonary infection, posaconazole prophylaxis was evaluated using three isogenic clinical isolates, with posaconazole MICs of 0.063 mg/liter (wild type), 0.5 mg/liter (F219I mutation), and 16 mg/liter. A fourth isolate harboring TR34/L98H (MIC of 0.5 mg/liter) was also tested. Posaconazole prophylaxis was effective in A. fumigatus with posaconazole MICs of ≤0.5 mg/liter, where 100% survival was reached. However, breakthrough infection was observed in mice infected with the isolate for which the posaconazole MIC was >16 mg/liter.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25534731      PMCID： PMC4325774          DOI： 10.1128/AAC.03850-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  54 in total

1.  First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany.

Authors:  P-M Rath; D Buchheidt; B Spiess; E Arfanis; J Buer; J Steinmann
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

Review 2.  The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.

Authors:  J W Mouton; D F J Brown; P Apfalter; R Cantón; C G Giske; M Ivanova; A P MacGowan; A Rodloff; C-J Soussy; M Steinbakk; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2012-01-20       Impact factor: 8.067

3.  Side population cells and Bcrp1 expression in lung.

Authors:  Ross Summer; Darrell N Kotton; Xi Sun; Bei Ma; Kathleen Fitzsimmons; Alan Fine
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03-07       Impact factor: 5.464

4.  Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Authors:  Alexander J Lepak; Karen Marchillo; Jaimie Vanhecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

5.  Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

6.  Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012.

Authors:  E Vermeulen; J Maertens; H Schoemans; K Lagrou
Journal:  Euro Surveill       Date:  2012-11-29

7.  Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Paul E Verweij; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

8.  Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.

Authors:  Jan W M van der Linden; Simone M T Camps; Greetje A Kampinga; Jan P A Arends; Yvette J Debets-Ossenkopp; Pieter J A Haas; Bart J A Rijnders; Ed J Kuijper; Frank H van Tiel; János Varga; Anna Karawajczyk; J Zoll; Willem J G Melchers; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2013-05-10       Impact factor: 9.079

9.  Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

10.  Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing.

Authors:  Simone M T Camps; Bas E Dutilh; Maiken C Arendrup; Antonius J M M Rijs; Eveline Snelders; Martijn A Huynen; Paul E Verweij; Willem J G Melchers
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
View more
  11 in total

1.  Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.

Authors:  S Seyedmousavi; Y C Chang; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.

Authors:  Silke Gastine; William Hope; Georg Hempel; Ruta Petraitiene; Vidmantas Petraitis; Diana Mickiene; John Bacher; Thomas J Walsh; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 4.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

Review 5.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

6.  In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 7.  Therapeutic Drug Monitoring of Posaconazole: an Update.

Authors:  Bart G J Dekkers; Martijn Bakker; Kim C M van der Elst; Marieke G G Sturkenboom; Anette Veringa; Lambert F R Span; Jan-Willem C Alffenaar
Journal:  Curr Fungal Infect Rep       Date:  2016-05-07

Review 8.  Pharmacokinetics and Pharmacodynamics of Posaconazole.

Authors:  Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

9.  In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Authors:  S Seyedmousavi; Y C Chang; J H Youn; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

10.  Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.

Authors:  Lore Vanderbeke; Nico A F Janssen; Roger J M Brüggemann; Joost Wauters; Dennis C J J Bergmans; Marc Bourgeois; Jochem B Buil; Yves Debaveye; Pieter Depuydt; Simon Feys; Greet Hermans; Oscar Hoiting; Ben van der Hoven; Cato Jacobs; Katrien Lagrou; Virginie Lemiale; Piet Lormans; Johan Maertens; Philippe Meersseman; Bruno Mégarbane; Saad Nseir; Jos A H van Oers; Marijke Reynders; Bart J A Rijnders; Jeroen A Schouten; Isabel Spriet; Karin Thevissen; Arnaud W Thille; Ruth Van Daele; Frank L van de Veerdonk; Paul E Verweij; Alexander Wilmer
Journal:  Intensive Care Med       Date:  2021-05-29       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.